Literature DB >> 25515804

Topical treatment with propranolol gel as a supplement to the existing treatment of hemangiomas.

Markus Schneider1, Andreas Reimer, Hansjoerg Cremer, Peter Ruef.   

Abstract

BACKGROUND: Systemic treatment with propranolol is proven to be effective for patients with hemangiomas with less side-effect. We used a propranolol gel for topical use on hemangiomas.
METHODS: In this retrospective study, we analyzed 148 patients who had been treated topically with propranolol gel for 12 weeks. We analyzed the data of patients and clinically gave each hemangioma a "hemangioma score" to determine the treatment success.
RESULTS: In 147 of the 148 patients, strong signs of resolution under treatment included lightening, paling, and less vascularization. The hemangioma score showed a significant decrease during the treatment. Relevant serum levels of propranolol were not found. Adverse effects were rare and not related to propranolol.
CONCLUSION: Topical treatment with propranolol gel is suitable for specific hemangiomas in addition to cryotherapy and systemic treatment with propranolol.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25515804     DOI: 10.1007/s12519-014-0509-6

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  13 in total

1.  Propranolol for severe hemangiomas of infancy.

Authors:  Christine Léauté-Labrèze; Eric Dumas de la Roque; Thomas Hubiche; Franck Boralevi; Jean-Benoît Thambo; Alain Taïeb
Journal:  N Engl J Med       Date:  2008-06-12       Impact factor: 91.245

2.  Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution.

Authors:  Suqin Guo; Nina Ni
Journal:  Arch Ophthalmol       Date:  2010-02

3.  Topical timolol for small hemangiomas of infancy.

Authors:  Matthias Moehrle; Christine Léauté-Labrèze; Verena Schmidt; Martin Röcken; Christian-F Poets; Rangmar Goelz
Journal:  Pediatr Dermatol       Date:  2012-04-04       Impact factor: 1.588

4.  Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas.

Authors:  Clemens Schiestl; Kathrin Neuhaus; Silke Zoller; Ulrike Subotic; Ishilde Forster-Kuebler; Rike Michels; Christian Balmer; Lisa Weibel
Journal:  Eur J Pediatr       Date:  2010-10-09       Impact factor: 3.183

5.  Topical propranolol for treatment of superficial infantile hemangiomas.

Authors:  Guangqi Xu; Renrong Lv; Zhongfang Zhao; Ran Huo
Journal:  J Am Acad Dermatol       Date:  2012-04-18       Impact factor: 11.527

6.  Propranolol for severe infantile hemangiomas: follow-up report.

Authors:  Véronique Sans; Eric Dumas de la Roque; Jérôme Berge; Nicolas Grenier; Franck Boralevi; Juliette Mazereeuw-Hautier; Dan Lipsker; Elisabeth Dupuis; Khaled Ezzedine; Pierre Vergnes; Alain Taïeb; Christine Léauté-Labrèze
Journal:  Pediatrics       Date:  2009-08-10       Impact factor: 7.124

7.  Evaluation of skin permeation of β-blockers for topical drug delivery.

Authors:  Doungdaw Chantasart; Jinsong Hao; S Kevin Li
Journal:  Pharm Res       Date:  2012-12-04       Impact factor: 4.200

8.  [Treatment of superficial infantile hemangiomas with topical propranolol].

Authors:  Jing-Ning Niu; Guang-Qi Xu; Ren-Rong Lü; Ran Huo
Journal:  Zhonghua Zheng Xing Wai Ke Za Zhi       Date:  2013-03

9.  [Effect of propranolol gel on infantile hemangiomas].

Authors:  Ya-Nan Zhai; Hong-Tao Song; Shao-Quan Chen; Min-Xin Zhang; Cheng-Jin Li; Yin Xia; Lie Wang
Journal:  Zhonghua Zheng Xing Wai Ke Za Zhi       Date:  2013-01

Review 10.  Are 1-2 tablets dangerous? Beta-blocker exposure in toddlers.

Authors:  Jeffrey N Love; Neal Sikka
Journal:  J Emerg Med       Date:  2004-04       Impact factor: 1.484

View more
  2 in total

1.  Effect of dosing regimen and microneedle pretreatment on in vitro skin retention of topically applied beta-blockers.

Authors:  Megan N Kelchen; Nicole K Brogden
Journal:  Biomed Microdevices       Date:  2018-12-06       Impact factor: 2.838

2.  The Influence of Formulation and Excipients on Propranolol Skin Permeation and Retention.

Authors:  Cristina Padula; Sara Nicoli; Silvia Pescina; Patrizia Santi
Journal:  Biomed Res Int       Date:  2018-08-02       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.